PA-PPG
24.5.2022 14:33:14 CEST | Business Wire | Press release
PPG (NYSE:PPG) today announced that it has committed to setting near-term company-wide emission reductions in line with climate science through the Science Based Target initiative (SBTi), which is an organization that helps companies define their decarbonization strategy and reduce the impacts of climate change.
PPG has an existing goal to reduce GHG emissions intensity by 15% by 2025 from a 2017 baseline, achieving a 9.7% reduction in 2021. The company has long reported emissions intensity from its own operations (Scope 1 emissions) and purchased electricity, steam, heating and cooling (Scope 2 emissions) and plans to unveil its new 2030 goals over the coming months. Moving forward, PPG is prioritizing evaluating indirect emissions that are from sources outside of the organization that PPG does not own or control, including raw materials, use of sold products, and product end-of-life (Scope 3 emissions).
“In this critical moment for climate change, we are committed to further evaluating and reducing emissions throughout our value chain,” said Diane Kappas, PPG vice president, Global Sustainability. “We are working across our organization to define additional actions we can take to help prevent the earth from warming more than 1.5 degrees Celsius. Following our validation work with SBTi and an emissions analysis, we intend to announce new, aggressive 2030 goals that will define our decarbonization strategy to help protect the planet for current and future generations.”
PPG also released its 2021 Environmental, Social and Governance (ESG) Report, which details advancements in its sustainable innovations, board governance of ESG, efforts to reach its 2025 sustainability goals and further actions to support customers’ sustainability goals. The full report is available at sustainability.ppg.com .
“Sustainability is at the heart of our purpose to protect and beautify the world,” said Kappas. “Our employees’ hard work and dedication helped us meet and surpass several of our near-term 2025 goals, and we continue to look for additional ways to reduce our emissions and overall environmental impact. While we are proud of our achievements, we recognize that now is the time for further action. We look forward to unveiling science-based targets as we complete the validation process.”
The latest report highlights PPG’s environmental actions and innovations globally. Key highlights include:
- Introduced PPG ERGOLUXE™ powder coatings, which offer first-pass transfer efficiency rates of up to 85% and the ability to reuse overspray. PPG ErgoLuxe Eco contains up to 13% recycled polyethylene terephthalate (rPET). Since 2017, PPG has used more than 6 million pounds of rPET to manufacture its coatings.
- Launched COMEX® TOP paint by PPG, which contributes to the circular economy by incorporating recycled tires, saving more than 270,000 tires from landfills since the product was introduced in 2021. The product is intended for application on roofs and provides thermal insulation, resulting in emissions reduction through energy savings.
- Implemented the Zero Discharge Project at Architectural Coatings facilities in the U.S. and Canada, enabling PPG to recycle and reuse more than 1.7 million gallons of water in its manufacturing process over the past two years.
- Installed a combined heat and power (CHP) unit at the Caivano, Italy, facility, creating an efficiency improvement equating to an annual reduction of approximately 1,100 metric tons of carbon dioxide (CO2 ).
- Invested more than $8.7 million between 2015 and 2021 in PPG’s global COLORFUL COMMUNITIES® initiative.
In 2021, PPG reduced process waste, increased renewable energy use in its facilities and increased sales from sustainably advantaged products. Highlights include:
- 38% of sales from sustainably advantaged products against the goal of 40% by 2025;
- 24% of electricity usage from renewable energy sources against the goal of 25% by 2025;
- 40% of manufacturing and research and development facilities with zero process waste to landfill, above the goal of 35% by 2025; and
- 37% reduction in waste disposal intensity from the 2017 baseline, above the goal of 25% by 2025.
To create strong and equitable communities, PPG worked to engage employees and diversify its recruiting and talent pools. Efforts focused on diversity, equity and inclusion (DE&I) include:
-
Unveiled new DE&I commitments:
- Achieve 34% to 36% representation of non-frontline global female professionals by 2025. PPG achieved 30% as of December 31, 2021.
- Increase representation of Black, Latino and Asian employees by 45% to 55% across our non-frontline, U.S.-based employee population (using January 1, 2021, as our baseline). At the end of 2021, PPG increased non-frontline Black employees by 13%, Latino employees by 9% and Asian employees by 8%.
- Achieve total global employee resource network (ERN) and DE&I capability-building participation of 50% by 2025. As of the end of 2021, PPG achieved 33% of this goal.
- Published the first PPG DE&I Report .
- Grew eight global ERNs to include more than 7,000 employee members across more than 60 countries.
- Invested $7.4 million through 2021 to advance racial equity in the U.S. by funding educational pathways for Black communities and people of color.
PPG’s 2021 reporting disclosures align with the Global Reporting Initiative (GRI) Standards and the Sustainability Accounting Standards Board (SASB) chemical standard. The company also strengthened its reporting against the United Nations Sustainable Development Goals (UN SDGs) and reported qualitative climate-related risks according to the Task Force on Climate-Related Financial Disclosures (TCFD).
To learn more about ESG at PPG and explore the report, visit sustainability.ppg.com .
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for nearly 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 75 countries and reported net sales of $16.8 billion in 2021. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .
We protect and beautify the world and ErgoLuxe are trademarks and Colorful Communities and the PPG Logo are registered trademarks of PPG Industries Ohio, Inc.
Comex is a registered trademark of Consorcio Comex, S.A. de C.V.
CATEGORY Sustainability
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
